



## Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference

September 22, 2021

NESS ZIONA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in the Cantor Global Healthcare Conference, taking place virtually from September 27<sup>th</sup> – 30<sup>th</sup>, 2021.

Cantor Global Healthcare Conference Presentation Information:	
Format	Fireside chat discussion and 1-on-1 meetings
Speaker:	Dr. Alon Seri-Levy, Chief Executive Officer and Mr. Gilad Mamlok, Chief Financial Officer
Date:	Thursday, September 30 <sup>th</sup>
Time:	Discussion available on demand beginning Thursday, September 30 <sup>th</sup> 10:40 a.m. ET (TRACK 3)
To Listen	To listen to the discussion, click <a href="#">here</a> . A replay will be archived for 30 days at this link (or go to <a href="http://www.sol-gel.com">www.sol-gel.com</a> to access within the Investors/Events and Presentations section).

### About Sol-Gel Technologies

Sol-Gel is a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for TWYNEO, which is FDA approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date that was set for April 26, 2021. Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre-approval inspection of the production site of EPSOLAY as a result of COVID-19 travel restrictions. Both product candidates are exclusively licensed for U.S. commercialization with Galderma.

The Company's pipeline also includes early-stage topical drug candidates SGT-210 (erlotinib gel) under investigation for the treatment of palmoplantar keratoderma, SGT-310 (tapinarof cream, 1%) and SGT-510 (roflumilast) under investigation for the treatment of plaque psoriasis and other dermatologic indications.

For additional information, please visit [www.sol-gel.com](http://www.sol-gel.com).

### Contact:

Irina Koffler  
Investor relations, LifeSci Advisors  
[ikoffler@lifesciadvisors.com](mailto:ikoffler@lifesciadvisors.com)  
+1-917-734-7387

### Sol-Gel Technologies

Gilad Mamlok  
Chief Financial Officer  
[gilad.mamlok@sol-gel.com](mailto:gilad.mamlok@sol-gel.com)



Source: Sol-Gel Technologies Ltd.